Literatuur
- Voskuilen CS et al. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: a convenient alternative to 5-fluorouracil. Radiother Oncol 2020; 150:275-80
- Bajorin DF et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. The New England journal of medicine 2021; 384:2102-14
- Bamias A et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Annals of oncology 2013; 24:1011-7
- Von der Maase H et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology 2005; 23:4602-8
- Powles T et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. The New England Journal of Medicine 2020; 383:1218-30
- Bellmunt J et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. The New England Journal of Medicine 2017; 376:1015-26
- Birtle A et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020; 395:1268-77
- Robertson AG et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2018; 174:1033
- Kamat AM et al. Bladder cancer. Lancet 2016; 388:2796-810
- James ND et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. The New England Journal of Medicine 2012; 366:1477-88
- Witjes JA et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - An international collaborative multistakeholder effort(dagger): under the auspices of the EAU-ESMO guidelines committees. European urology 2020; 77:223-50
- Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. The New England Journal of Medicine 2021; 384:1125-35
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over blaascarcinoom.
Ga naar de commissie BOM adviezen over urotheelcelcarcinoom.